Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

PMID:
31171773
2.

PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q.

JCI Insight. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607.

3.

PRL-3 activates mTORC1 in Cancer Progression.

Ye Z, Al-Aidaroos AQ, Park JE, Yuen HF, Zhang SD, Gupta A, Lin Y, Shen HM, Zeng Q.

Sci Rep. 2015 Nov 24;5:17046. doi: 10.1038/srep17046.

4.

Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.

Wang H, Liu B, Al-Aidaroos AQ, Shi H, Li L, Guo K, Li J, Tan BC, Loo JM, Tang JP, Thura M, Zeng Q.

Oncogene. 2016 Jun 23;35(25):3303-13. doi: 10.1038/onc.2015.391. Epub 2015 Oct 12.

5.

A role of autophagy in PTP4A3-driven cancer progression.

Huang YH, Al-Aidaroos AQ, Yuen HF, Zhang SD, Shen HM, Rozycka E, McCrudden CM, Tergaonkar V, Gupta A, Lin YB, Thiery JP, Murray JT, Zeng Q.

Autophagy. 2014 Oct 1;10(10):1787-800. doi: 10.4161/auto.29989. Epub 2014 Aug 1.

6.

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.

Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, Zhang SD, Chng WJ, Hong CW, Mills K, Zeng Q.

EMBO Mol Med. 2013 Sep;5(9):1351-66. doi: 10.1002/emmm.201202183. Epub 2013 Aug 8.

7.

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.

Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, Zeng Q.

J Clin Invest. 2013 Aug;123(8):3459-71. doi: 10.1172/JCI66824. Epub 2013 Jul 8. Erratum in: J Clin Invest. 2013 Oct 1;123(10):4540.

8.

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.

Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, Zhang HF, Zeng Q.

BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.

9.

Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.

Guo K, Tang JP, Jie L, Al-Aidaroos AQ, Hong CW, Tan CP, Park JE, Varghese L, Feng Z, Zhou J, Chng WJ, Zeng Q.

Oncotarget. 2012 Feb;3(2):158-71.

10.

Targeting intracellular oncoproteins with antibody therapy or vaccination.

Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C, Zeng Q.

Sci Transl Med. 2011 Sep 7;3(99):99ra85. doi: 10.1126/scitranslmed.3002296.

11.

PRL-3 phosphatase and cancer metastasis.

Al-Aidaroos AQ, Zeng Q.

J Cell Biochem. 2010 Dec 1;111(5):1087-98. doi: 10.1002/jcb.22913. Review.

PMID:
21053359

Supplemental Content

Loading ...
Support Center